This IL1–IL6 cycle intensifies systemic inflammation (e.g., increasing C-reactive protein) and shapes a tumor-promoting environment by recruiting immune-suppressive cells and fostering angiogenesis, aiding tumor survival and immune evasion [208]. This evidence concerns the gene CRP and neoplasm.